Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs.
How would you describe Biogen’s longstanding presence within the UK marketplace?
"Our ambition is to be positioned right at the sharp end of scientific progress and to successfully translate that into meaningful medicines in areas of high unmet need."
